Kyverna Therapeutics, Inc.(KYTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KYTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Kyverna Therapeutics, Inc. (KYTX), a Healthcare sector company. KYTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of KYTX by reported 13-F value include GordonMD Global Investments, GILEAD SCIENCES, BlackRock, based on the most recent SEC filings. KYTX trades on the Nasdaq exchange and files with the SEC under CIK 1994702. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kyverna Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-38.3M
D/E Ratio
Q2 2026
0.15
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-26.5% YoYOperating Income
-19.1% YoYEPS (Diluted)
-9.3% YoYTotal Assets
-3.6% YoYTotal Debt
Op. Cash Flow
-34.5% YoYFree Cash Flow
-32.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-161.3M -26.5% | $-127.5M -111.2% | $-60.4M | — |
| Operating Income | $-169.8M -19.1% | $-142.6M -128.5% | $-62.4M | — |
| EPS (Diluted) | $-3.64 -9.3% | $-3.33 +96.3% | $-89.61 | — |
| Total Assets | $293.8M -3.6% | $304.6M +305.1% | $75.2M | — |
| Total Debt | $24.7M | — | — | — |
| Operating Cash Flow | $-153.7M -34.5% | $-114.3M -118.0% | $-52.4M | — |
| Free Cash Flow | $-153.7M -32.0% | $-116.5M -119.6% | $-53.0M | — |
Get alerted when KYTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kyverna Therapeutics, Inc. including:
Top Institutional Holders of KYTX
GordonMD Global Investments LP
$37.8M4,244,818 shGILEAD SCIENCES, INC.
$36.8M4,126,119 shBlackRock, Inc.
$27.9M3,134,807 shBain Capital Life Sciences Investors, LLC
$25.7M2,885,000 shAIGH Capital Management LLC
$24.9M2,795,797 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$17.8M2,000,000 shVANGUARD CAPITAL MANAGEMENT LLC
$16.9M1,897,451 shPRICE T ROWE ASSOCIATES INC /MD/
$10.6M1,186,023 shGEODE CAPITAL MANAGEMENT, LLC
$9.4M1,049,430 shInsight Holdings Group, LLC
$8.8M989,054 sh
| Fund | Value | Shares |
|---|---|---|
| GordonMD Global Investments LP | $37.8M | 4,244,818 |
| GILEAD SCIENCES, INC. | $36.8M | 4,126,119 |
| BlackRock, Inc. | $27.9M | 3,134,807 |
| Bain Capital Life Sciences Investors, LLC | $25.7M | 2,885,000 |
| AIGH Capital Management LLC | $24.9M | 2,795,797 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $17.8M | 2,000,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.9M | 1,897,451 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $10.6M | 1,186,023 |
| GEODE CAPITAL MANAGEMENT, LLC | $9.4M | 1,049,430 |
| Insight Holdings Group, LLC | $8.8M | 989,054 |
More Healthcare Companies
View all Healthcare →Put KYTX on your watchlist
Track score changes the day Kyverna Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KYTX a good stock to buy?
13F Pro's AI-powered analysis of Kyverna Therapeutics, Inc. (KYTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KYTX are available on the KYTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KYTX is classified as a small company.
Which hedge funds own KYTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KYTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kyverna Therapeutics, Inc.'s investment landscape.